Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.77% as of August 15, 2025, with notable gains from companies such as BeiGene (1.78%) and Innovent Biologics (1.67%) [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.60%, marking its third consecutive increase, with the latest price at 1.01 yuan [3] - Over the past week, the Hong Kong Innovative Drug Selection ETF has accumulated a rise of 2.76% [3] Group 2 - According to Guojin Securities, China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large-scale transactions in BD authorization [4] - In the oncology sector, two main directions are highlighted: the multidimensional iteration of ADC (antibody-drug conjugates) and innovations in the molecular components of immunotherapy [4] - The latest scale of the Hong Kong Innovative Drug Selection ETF reached 396 million yuan, a new high since its establishment [4] Group 3 - The top ten weighted stocks in the HSSCPB index account for 77.96% of the index, including companies like BeiGene and WuXi Biologics [5] - The Hong Kong Innovative Drug Selection ETF closely tracks the HSSCPB index, which reflects the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5]

8月14日恒生指数下跌0.37%，报收25519.32点，全天南向资金通过港股通渠道合计净买入10.34亿港 元。 证券时报·数据宝统计，8月14日港股通全天合计成交金额为1475.43亿港元，成交净买入10.34亿港元。 具体来看，沪市港股通成交金额927.12亿港元，成交净买入16.45亿港元；深市港股通成交金额548.31亿 港元，成交净卖出6.11亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，腾讯控股成交额为60.03亿港元，成交金额居首； 其次是阿里巴巴-W、中芯国际，成交金额分别为36.89亿港元、36.59亿港元。以净买卖金额统计，中国 人寿净买入额为13.53亿港元，净买入金额居首，该股收盘股价上涨3.60%。净卖出金额最多的是腾讯控 股，净卖出6.78亿港元，收盘股价上涨0.68%。 深市港股通前十大成交活跃股中，成交额居首的是腾讯控股，成交金额41.88亿港元；其次是中芯国 际、阿里巴巴-W，成交金额分别为21.29亿港元、21.23亿港元。以净买卖金额统计，有5只股为净买 入，净买入金额最多的是阿里巴巴-W，净买入3.13亿港元，该股收盘下跌1.54%。净卖出金额最多的是 腾讯 ...

8月14日消息，南向资金今日成交1475.43亿港元，净流入约10.34亿港元。其中沪港股通净流入约16.45 亿港元，深港股通净流出约6.11亿港元 交易所数据显示，8月14日南向资金动向： 大幅净买入：中国人寿(02628.HK)13.53亿港元、阿里巴巴-W(09988.HK)4.55亿港元、理想汽车- W(02015.HK)3.52亿港元、三生制药(01530.HK)3.04亿港元、康方生物(09926.HK)2.22亿港元、中芯国际 (00981.HK)1.62亿港元。 大幅净卖出：腾讯控股(00700.HK)119698.80万港元、美团W(03690.HK)38634.16万港元、晶泰控股 (02228.HK)25483.83万港元、药明生物(02269.HK)18831.93万港元。 成交详情 中国人寿今日涨3.60%，沪港股通净买入13.53亿港元。 晶泰控股今日涨11.61%，沪港股通净卖出13421.88万港元，深港股通净卖出12061.94万港元。 药明生物今日涨0.06%，深港股通净卖出18831.93万港元。 本文源自：金融界 阿里巴巴W今日跌1.54%，沪港股通净买入1.42亿港 ...

该行上调对信达生物(01801)目标价10%，从100港元升至110港元，评级"跑赢大市"。该行对该公司达到 该行全年产品收入增长预测同比增37%非常有信心。 该行依旧关注中国创新药的授权许可交易，同时，对于高价创新药也会有更多补贴，这或许可以驱动销 售量的增长，其中涉及到科济药业-B(02171)、复星医药(02196)、药明巨诺-B(02126)以及科伦博泰生物- B(06990)等。 该行认为康方生物(09926)预计上半年经调整盈利预计将为2300万元人民币，主要受惠于旗下药物 AK104和AK112的收入增长，评级"跑赢大市"。 智通财经APP获悉，建银国际发布研报称，对中国医药行业维持审慎乐观的态度。该行指出，2025年初 至今，港股生物科技股份平均上涨137%，主要受惠于创新药授权交易的现金回赠以及任何即将到来的 美国关税却不受到影响。该行业近期出现一些回调，原因是：1)一些大型生物科技公司2025年上半年的 业绩显示，其药品销售额差于预期，包括和黄医药(00013);2)市场担心特朗普计划分阶段征收一系列药 品关税，这些关税可能在一年半内达到150%，然后最终上升到250%。 该行的首选是20 ...

格隆汇8月14日丨康方生物(09926.HK)公告，公司将于2025年8月26日(星期二)举行董事会会议，藉以(其 中包括)考虑及批准公司及其附属公司于截至2025年6月30日止6个月中期业绩及其发布。 ...

康方生物科技（ 開曼 ）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二五年八月二十六日（ 星期二 ）舉行董事會會議，藉以（ 其中包括 ）考慮及批 准本公司及其附屬公司於截至二零二五年六月三十日止六個月之中期業績及其發 佈。 承董事會命 康方生物科技（開曼）有限公司 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9926） 董事會會議召開日期 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 主席兼執行董事 夏瑜博士 香港，二零二五年八月十四日 於 本 公 告 日 期 ， 董 事 會 成 員 包 括 主 席 兼 執 行 董 事 夏 瑜 博 士 ， 執 行 董 事 李 百 勇 博 士、王忠民博士及張鵬博士，非執行董事謝榕剛先生，獨立非執行董事曾駿文博 士、徐岩博 ...

Core Viewpoint - 康方生物's stock rose over 4%, currently at 164.6 HKD with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody drug, Ivoris, during the conference, specifically the Phase III HARMONi study results, which have been selected for a Late-Breaking Abstract presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in patients with immune therapy-resistant lung cancer, which has been included in the Mini Oral session of the conference [1] - The combination therapy of Cardonili has previously been recognized as a breakthrough therapy for advanced squamous non-small cell lung cancer (NSCLC) after progression on PD-(L)1 inhibitors, highlighting its significant clinical value [1]

消息面上，康方生物今日公布，2025年世界肺癌大会（WCLC）将于9月6日-9日在西班牙巴塞罗那举 行。会议期间，康方生物海外合作伙伴Summit Therapeutics，将重磅发布公司全球首创PD-1/VEGF双特 异性抗体新药依沃西首个国际多中心注册性Ⅲ期临床HARMONi研究的结果，该研究结果作为Late- Breaking Abstract（LBA）被大会选为口头报告，将在全体会议主席专题研讨会（Presidential Symposium）上重磅发布。 此外，会议期间，康方生物还将公布卡度尼利和普络西单抗（VEGFR2）联合疗法在免疫治疗（IO）耐 药肺癌人群的疗效数据，该研究成果入选大会的Mini Oral。此前，卡度尼利该联合疗法治疗经PD-(L)1 抑制剂治疗后进展的晚期鳞状非小细胞肺癌（NSCLC）被纳入突破性治疗品种名单，体现该联合疗法 的重大突破性临床价值。 康方生物(09926)涨超4%，截至发稿，涨4.44%，报164.6港元，成交额14.04亿港元。 ...

Core Viewpoint - 康方生物's stock rose over 4%, reaching 164.6 HKD, with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody new drug, Ivoris, during the conference, which has been selected for a Late-Breaking Abstract oral presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in the context of immune therapy-resistant lung cancer, which has been included in the conference's Mini Oral session [1] - The combination therapy of Cardonili has been recognized as a breakthrough treatment for advanced squamous non-small cell lung cancer (NSCLC) after progression on PD-(L)1 inhibitors, highlighting its significant clinical value [1]

Key Points - Xiaomi Group-W (01810), Crystal International Holdings (02228), and BYD Electronic (00285) ranked top in net inflow of southbound funds, with net inflows of 562 million, 227 million, and 213 million respectively [1][2] - Xpeng Motors-W (09868), Innovent Biologics (01801), and Ganfeng Lithium (01772) had the highest net outflows, with net outflows of -663 million, -535 million, and -410 million respectively [1][2] - In terms of net inflow ratio, Haitian Flavoring and Food (03288), Jiangsu Nanjing Highway (00177), and Swire Properties B (00087) led the market with ratios of 55.51%, 49.37%, and 46.46% respectively [1][2] - The highest net outflow ratios were recorded by Reshape Energy (02570), Southbound Hang Seng Index ETF (03037), and First Pacific Company (00142) with ratios of -90.77%, -68.70%, and -60.36% respectively [1][3] Net Inflow Rankings - Xiaomi Group-W (01810) had a net inflow of 562 million, representing 8.75% of its closing price of 50.800, which decreased by 0.88% [2] - Crystal International Holdings (02228) saw a net inflow of 227 million, with a net inflow ratio of 11.34% and a closing price of 7.450, which increased by 4.78% [2] - BYD Electronic (00285) recorded a net inflow of 213 million, with a net inflow ratio of 13.41% and a closing price of 38.680, which increased by 6.15% [2] Net Outflow Rankings - Xpeng Motors-W (09868) experienced the largest net outflow of -663 million, with a net outflow ratio of -20.13% and a closing price of 83.600, which increased by 5.36% [2] - Innovent Biologics (01801) had a net outflow of -535 million, with a net outflow ratio of -19.67% and a closing price of 89.950, which decreased by 1.42% [2] - Ganfeng Lithium (01772) recorded a net outflow of -410 million, with a net outflow ratio of -19.45% and a closing price of 34.000, which increased by 20.91% [2] Net Inflow Ratio Rankings - Haitian Flavoring and Food (03288) had a net inflow ratio of 55.51%, with a net inflow of 21.1399 million and a closing price of 33.560, which decreased by 0.47% [3] - Jiangsu Nanjing Highway (00177) recorded a net inflow ratio of 49.37%, with a net inflow of 14.6726 million and a closing price of 9.980, which decreased by 0.40% [3] - Swire Properties B (00087) had a net inflow ratio of 46.46%, with a net inflow of 4.0945 million and a closing price of 12.160, which decreased by 0.57% [3]